GlassScriptPhysician profile
Alexandra Huffman
NPI 1578186862
$3,884.31
in general payments reported to CMS, 2019-2025
24 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.00 · 2023: $750 · 2024: $1,994 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,700 · Education: $94.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,699.53 |
| Education | $94.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $870.98 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $664.50 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $412.52 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $364.26 | 2023-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.86 | 2023-2024 | Xifaxan, Trulance |
| Pfizer INC. | $144.18 | 2023-2025 | |
| Qol Medical, LLC | $133.68 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $130.42 | 2023-2025 | Dupixent |
| Celltrion USA INC. | $127.42 | 2024-2025 | Zymfentra, Vegzelma |
| Celgene Corporation | $103.73 | 2023-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $92.78 | 2024-2025 | Rebyota |
| Biogen, INC. | $90.00 | 2021 | |
| Ironwood Pharmaceuticals, INC | $83.10 | 2024-2025 | |
| Genzyme Corporation | $63.00 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $62.99 | 2025 | Iqirvo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $62.08 | 2024 | Voquezna |
| Gilead Sciences, INC. | $61.15 | 2024-2025 | |
| Daiichi Sankyo INC. | $51.04 | 2024-2025 | Injectafer |
| Intercept Pharmaceuticals, INC. | $38.63 | 2023-2025 | Ocaliva |
| Tersera Therapeutics LLC | $36.94 | 2023 | Xermelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.00 | 2023 | Cyltezo |
| Lilly USA, LLC | $24.51 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $19.46 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $14.08 | 2025 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.